S_ry 1The pattern of expression of the c-erbB-2 oncoprotein was investigatdd in whole mount preparations of 11 human fetuses by immunocytochemistry using two polyclonal antibodies, 20N and 21N. c-erbB-2 was widely expressed within all three germ layers. Expression remained relatively constant in epitheliaL mesodermal and extraembryonic tissues, but varied over time during the development of the fetal skeleton. Western blotting failed to detect c-erbB-2 in normal fetal tissues but did confirm expression in a microvillous membrane preparation of placenta. c-erbB-2 expression is widespread in the human fetus and occurs at an earlier stage than epidermal growth factor receptor.
The c-erbB-2 proto-oncogene encodes a 4.6 kb mRNA which specifies a 190,000 molecular weight glycoprotein with tyrosine kinase activity. This 1,255 amino acid protein reveals extensive sequence homology with the epidermal growth factor receptor (EGF-R), but unlike EGF-R, no ligand has yet been identified (for a review see Gullick & Venter, 1989) . Amplification of the c-erbB-2 proto-oncogene has been demonstrated in a wide range of adenocarcinomas including those of the breast (Slamon et al., 1987; Venter et al., 1987; Van de Vijver et al., 1987 , 1988 , stomach (Yokota et al., 1986 (Yokota et al., , 1988 , salivary gland (Semba et al., 1985) , kidney (Yokota et al., 1986 ) and lung (Cline & Battifora, 1987 ) and appears to be related to prognosis in breast cancer (Slamon et al., 1987; Zhou et al., 1987) . The presence of amplification in colonic adenocarcinoma has been reported (Tal et al., 1988) , but it is unclear if this is a frequent event as it has not been detected by other workers (Yokota et al., 1986) .
The physiological action of the c-erbB-2 receptor protein is unknown and its distribution in human fetal and normal tissue has yet to be fully characterised. c-erbB-2 mRNA was widely expressed in organ digests from a single human fetus (Coussens et al., 1985) but its site within these tissues has not been identified. Expression of the neu oncogene, the rat equivalent of c-erbB-2, with which it has 88% homology, has been described in fetal rats (Kokai et al., 1987) (Drebin et al., 1985 (Drebin et al., , 1986 Bernards et al., 1987) or anti-oncogene therapy.
We have investigated the presence and distribution of the c-erbB-2 protein by immunocytochemistry and Western blotting in a series of human fetuses and placentae using two previously described polyclonal antibodies .
Materials and methods
Fifteen whole human fetuses from spontaneous abortions were collected over several years and stored in 10% formalin. After processing and embedding four were discarded owing to the presence of mild to severe autolysis, leaving 11 well preserved fetuses for study. Estimated gestational ages were determined by a combination of foot length, crown rump length and histological assessment of tissue maturity and ranged from 6 to 12 weeks. Fetuses larger than 12 weeks could not be sectioned whole and were therefore not included in this study. Tissue from first trimester, second trimester and term placentae was also studied.
Immunocytochemistry
The rabbit polyclonal antibodies used were previously designated 20N and 21N This was performed as previously described (Gullick et al., 1986) on tissued extracts from a single human fetus (estimated gestational age 12 weeks). Placental vesicles were prepared from human term placenta (Smith et al., 1977 (Figure 3c and d) . This was maximal towards the periphery of the lung from 8 to 10 weeks. At 12 weeks only the bronchial epithelium was staining.
Gastrointestinal system
The epithelial lining of the gut stained whenever it was present in the sections; oesophageal, gastric, small intestinal and colonic epithelium stained diffusely but with luminal 
Skin
The epidermis retained its diffuse positivity as the squamous epithelium increased in thickness (Figure 3a) . The underlying mesenchyme revealed a variable distribution of staining both with time and site from negative to intensely positive. The intensity was always greatest nearest to the basement membrane.
Placenta
Intense staining of cyto-and syncytiotrophoblast was seen for all trimesters.
Western blotting
In order to confirm the pattern of c-erbB-2 expression observed by immunohistological staining, we prepared extracts from a variety of normal human fetal tissues and performed Western blotting using the 21N antibody. Extracts prepared from the human breast cancer cell line SKBR-3, which has a 4-8-fold amplification of the c-erbB-2 gene, gave a single band of 190,000 mol. wt (Figure 4 , tracks 1-3).
Despite several attempts using extracts from fetal tissues we only obtained a band of the appropriate molecular weight in extracts prepared from concentrated human placental vesicles (Figure 4 , tracks 4-6). Concentration of membrane glycoproteins, including the c-erbB-2 protein, using wheat germ agglutinin sepharose or immunoprecipitation, did not increase the sensitivity of detection sufficiently to allow identification of the c-erbB-2 protein in extracts of other tissue.
The pattern of staining of the c-erbB-2 protein has been investigated in whole mount fetus preparations during the first trimester of pregnancy, a period of rapid organogenesis of nearly all the major adult organ systems. Spontaneous abortion material was selected which showed no morphological abnormality and no evidence of autolysis. Of the two antibodies, 21N gave stronger staining than 20N at the same dilutions. Both antibodies, however, gave identical staining patterns with the exception of red blood cells where the strong positivity for the 21N antibody but not 20N suggests that this may be a non-specific cross-reaction. This pattern of reactivity was also seen with non-nucleated adult red blood cells (unpublished observations).
Expression of the c-erbB-2 oncoprotein was found extensively within all three germ layers in the developing human fetus suggesting an important role in embryogenesis. Expression remained relatively constant in tissues derived from epidermal, endodermal, mesodermal and extraembryonic ongins, e.g. muscle, neural tissue and trophoblast; but during the development of the fetal skeleton it varied over time. The close co-expression of c-erbB-2 in developing epithelium and its surrounding mesenchyme, as seen in the lung, skin and gut, suggests that the c-erbB-2 receptor and its putative ligand may play a role in mesenchymal-epithelial communications.
The pattern of expression in the human is remarkably similar to a study of neu in the fetal rat (Kokai et al., 1987) and confirms the mRNA work of Coussens et al., (1985) on a single human fetus. As in the present study, Kokai et al. (1987) , using different antibodies specific for the rat neu protein, i.e. 7.16.4, 7.9.5 and 7.21.2, detected immunocytochemical staining in the skin, bronchial and gut epithelium, renal tubules, nervous system, etc.
Western blotting of fresh fetal tissue failed to identify the c-erbB-2 protein. This approach, however, was successful when applied to vesicles isolated from extra-embryonic tissue, the placenta, confirming the immunocytochemical localisation of this oncoprotein. Comparison of the levels of expression in Figure 4 suggests that the concentrated placental preparation contained 30-50 fold less c-erbB-2 protein per microgram of total protein than do SKBR-3 cells. Hutman placenta has been reported to contain approximately 5 times as much mRNA for c-erbB-2 than other fetal tissues (Coussens et al., 1985) . These results suggest that in the absence of specific sensitive radioimmunoassays for the c-erbB-2 protein, immunocytochemistry remains the best method of detecting c-erbB-2 protein when expressed at relatively low levels in normal tissues.
The widespread expression of the c-erbB-2 gene and its consistent presence in all three embryonic layers places it on a par with the myc (Zimmerman et al., 1986) and ras (Muller et al., 1982; Furth et al., 1987) families as a gene with a general role in fetal development. Other proto-oncogenes, such as c-ros (Neckameyer et al., 1986) , c-src (Cotton & Brugge, 1983; Sorge et al., 1984; Neckameyer et al., 1986) and the int family (Jakobovits et al., 1986) appear to have a much more limited tissue distribution and may be involved in differentiated functions.
Human fetal epidermal growth factor receptor (EGF-R) expression has recently been reported by Oliver (1988) , who showed immunocytochemical evidence of limited expression after 16 weeks of age (see Table I ), but none before this, suggesting that EGF-R has a different role and is less important in early fetal development than the c-erbB-2 protein. The promoter regions of the EGF receptor (Ishii et al., 1985) and c-erbB-2 genes (Ishii et al., 1987; Tal et al., 1987) differ in structure suggesting that different factors control their rate of transcription.
Growth factor gene expression has been reported for transforming growth factor-a and P in the fetal mouse.
TGF-x was detected in fetal but not placental extracts from day 7 to day 13, a period of intense organogenesis (Twardzik, 1985) , epidermal growth factor being absent during this period. In situ mRNA hybridisation confirmed the former but also detected TGF-x in placental syncytiotrophoblast (Wilcox & Derynck, 1988 have recognised all the subclasses of TGF-#.
The marked expression of c-erbB-2 reported in this study in trophoblast is reminiscent of previous work describing c-myc, c-sis, c-fnms, PDGF receptor and EGF-R activity in the same population of cells (Muller et al., 1983; Goustin et al., 1985; Oliver, 1988) . The high levels of proto-oncogene expression possibly relating to the unusual invasive behaviour of trophoblast.
The presence of c-erbB-2 abnormalities in salivary, gastric, renal, pulmonary and colonic adenocarcinoma (see Gullick & Ventner, 1989; Tal et al., 1988) and in experimental neural tumours (Lantos et al., 1986; Perantoni et al., 1987) 
